Market openNon-fractional

Relay Therapeutics/RLAY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Relay Therapeutics

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Ticker

RLAY

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

309

RLAY Metrics

BasicAdvanced
$832M
Market cap
-
P/E ratio
-$2.63
EPS
1.66
Beta
-
Dividend rate
$832M
1.66
20.733
20.181
6.324
7.014
-24.58%
-40.40%
22.178
1.11
1.11
-2.725
2,873.65%
-5.74%
-24.96%
-11.96%

What the Analysts think about RLAY

Analyst Ratings

Majority rating from 12 analysts.
Buy

RLAY Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-813.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-60.78%
Net income
-$81M
-76.22%
Profit margin
-813.00%
-39.36%

RLAY Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.05%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.81
-$0.54
-$0.67
-$0.62
-
Expected
-$0.82
-$0.83
-$0.73
-$0.70
-$0.73
Surprise
-0.69%
-35.00%
-8.01%
-12.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Relay Therapeutics stock?

Relay Therapeutics (RLAY) has a market cap of $832M as of July 05, 2024.

What is the P/E ratio for Relay Therapeutics stock?

The price to earnings (P/E) ratio for Relay Therapeutics (RLAY) stock is 0 as of July 05, 2024.

Does Relay Therapeutics stock pay dividends?

No, Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Relay Therapeutics dividend payment date?

Relay Therapeutics (RLAY) stock does not pay dividends to its shareholders.

What is the beta indicator for Relay Therapeutics?

Relay Therapeutics (RLAY) has a beta rating of 1.66. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Relay Therapeutics stock

Buy or sell Relay Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing